Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial.

R Scott WrightFrederick J RaalWolfgang KoenigUlf LandmesserLawrence Alan LeiterSheikh VikarunnessaAnastasia LesogorPierre MaheuxZsolt TalloczyXiao ZangGregory G SchwartzKausik K Ray

Published in: Cardiovascular research (2024)

In the largest and longest follow-up to date, inclisiran demonstrated sustained and substantial LDL-C lowering with a favourable long-term safety and tolerability profile. ClinicalTrials.gov identifier: NCT03814187.

Keyphrases

open label
phase iii
low density lipoprotein
phase ii
study protocol
preterm infants
clinical trial
gestational age
randomized controlled trial